GSK: Result Summaries: Compounds

Result Summaries: nelarabine

GSK Study ID	Phase	Title
PGA105446	phase 1	Clinical Evaluation of 506U78 in Japanese Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma. (1 citation(s))
PGAA1001	Phase 1	A phase I study of 2-amino-9-b-D-arabinofuranosyl-6-methoxy-9H-purine (Compound 506) in children and adults with refractory hematologic malignancies. (3 citation(s))
PGAA1002	Phase 1	A phase I study of 506U78 administered as a two hour infusion daily for 3 consecutive days in adult patients and as a two hour infusion daily over 5 consecutive days in pediatric patients with refractory hematologic malignancies. (0 citation(s))
PGAA1003	Phase 1	Phase I study of 506U78 administered as a two hour infusion on a day 1, 3, and 5 schedule in patients with refractory hematologic malignancies. (0 citation(s))
PGAA1005	Phase 1	Pilot study of pharmacodynamic investigation of treatment with 506U78 combined with fludarabine in refractory leukemics. (2 citation(s))
PGAA2001	Phase 2	A Phase II Study of 506U78 in Patients with Refractory T-Cell Malignancies – CCG Intergroup Study (1 citation(s))
PGAA2003	Phase 2	A Multicenter Study to Assess the Efficacy of 506U78 in Subjects with Chronic Lymphocytic Leukemia (CLL) who are Refractory to Fludarabine and Alkylator Therapy (0 citation(s))